Remarkably, any significant effect on normal CD34+ cell survival failed to be detected, suggesting that targeting NOX2-driven mitochondrial transfer appears to be a novel therapeutic strategy in AML. The gene discussed is CD34; the disease is acute myeloid leukemia.